Compare WEST & PRTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WEST | PRTC |
|---|---|---|
| Founded | 2009 | 2015 |
| Country | United States | United States |
| Employees | 1408 | N/A |
| Industry | Beverages (Production/Distribution) | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 428.0M | 464.3M |
| IPO Year | N/A | N/A |
| Metric | WEST | PRTC |
|---|---|---|
| Price | $3.99 | $16.81 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $9.00 | N/A |
| AVG Volume (30 Days) | ★ 262.3K | 4.4K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $39.88 | N/A |
| Revenue Next Year | $14.87 | N/A |
| P/E Ratio | ★ N/A | $8.09 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.59 | $13.30 |
| 52 Week High | $7.92 | $20.00 |
| Indicator | WEST | PRTC |
|---|---|---|
| Relative Strength Index (RSI) | 32.08 | 48.59 |
| Support Level | $3.95 | $16.51 |
| Resistance Level | $4.67 | $18.10 |
| Average True Range (ATR) | 0.21 | 0.49 |
| MACD | -0.11 | -0.08 |
| Stochastic Oscillator | 24.81 | 44.66 |
Westrock Coffee Co is an integrated coffee, tea, flavors, extracts, and ingredients solutions provider in the U.S, providing coffee sourcing, supply chain management, product development, roasting, packaging, and distribution services to retail, foodservice and restaurant, convenience store and travel center, non-commercial account, CPG, and hospitality industries around the world. The company's segment includes Beverage Solutions and Sustainable Sourcing and Traceability. It generates maximum revenue from the Beverage Solutions segment.
PureTech Health PLC, together with its subsidiaries, is a clinical-stage biopharma company developing medicines to modulate the adaptive human system. The company is focused on developing and commercializing differentiated medicines for devastating diseases, including inflammatory, immunological conditions, intractable cancers, lymphatic & gastrointestinal diseases, and neurological and neuropsychological disorders, among others. Its drug development pipeline consists of Deupirfenidone (LYT-100), for the potential treatment of idiopathic pulmonary fibrosis (IPF), LYT-200, SPT-300, an oral drug for depressive disorder, SPT-320, and others. The company's operating segments include Parent Companies & Other, which derives key revenue, Wholly-Owned Programs, and Controlled Founded Entities.